Sun Pharmaceutical Industries (SUNPHARMA) reported quarterly profit ahead of analyst expectations on Friday, driven by strong demand for its higher-margin specialty medicines, but rising costs eroded profitability and pushed shares lower.

AstraZeneca (AZN) and its Japanese partner Daiichi Sankyo (DSNKY) have secured US regulatory approval for Datroway in triple-negative breast cancer, marking a significant milestone in an intensifying battle with Gilead Sciences (GILD) for dominance in one of oncology's most contested markets.

Guggenheim has initiated coverage of Avalyn Pharma (AVLN) with a buy rating and a price target of $80, implying roughly 177 per cent upside from its current level of $28.84 and valuing the company at $1.21bn on a market capitalisation basis.

Nestlé (NSRGY) and Danone (DANOY) are facing renewed regulatory and reputational pressure after a joint investigation by French, Belgian and Swiss public broadcasters alleged that both companies were slow to alert European authorities to the presence of a harmful toxin in infant formula products.

Takeda Pharmaceutical (TAK) faces a damages bill that could reach $2.5bn after a federal jury in Boston found the Japanese drugmaker liable in what legal experts are calling a landmark antitrust case, the first time a pharmaceutical company has been found liable by a federal jury in a so-called pay-for-delay suit.

ROCHE (RHHBY) has agreed to allow generic manufacturers to produce its influenza antiviral baloxavir marboxil, signing a voluntary licence with the Medicines Patent Pool in a move that could significantly expand access to the drug across the developing world.

BioMarin Pharmaceutical reported mixed Phase 3 results for experimental rare disease therapy BMN 401, raising uncertainty around the drug’s regulatory prospects and adding pressure to the company’s efforts to diversify its revenue base.

Novartis terminated a manufacturing and facility leasing agreement with Chinese CDMO Porton Pharma Solutions following a dispute tied to regulatory issues at a production site in Slovenia.

AstraZeneca received U.S. approval for hypertension treatment Baxfendy, giving the drugmaker a new entrant into the large and highly competitive cardiovascular market.

The therapy, also known as baxdrostat, was approved for use alongside existing blood pressure medications in patients with uncontrolled hypertension.

The U.S. Supreme Court declined to hear a pharmaceutical industry challenge against the Biden-era Medicare drug price negotiation programme, leaving in place lower court rulings that upheld the policy under the Inflation Reduction Act.

Merck & Co. said its experimental cancer therapy sacituzumab tirumotecan (sac-TMT) improved survival and delayed disease progression in patients with advanced or recurrent endometrial cancer in a late-stage trial.

Eli Lilly (LLY) has claimed top position in both principal categories of a prominent annual ranking of pharmaceutical research and development performance, the first time a single company has achieved the feat since the index was established.

The White House has added more than 600 generic medicines to TrumpRx.gov, its government-run drug price comparison portal, in an attempt to address a significant gap in the platform's coverage since its launch earlier this year.

The World Health Organization is racing to contain a growing Ebola outbreak in the Democratic Republic of Congo, with a further six tonnes of medical supplies due to land on Tuesday as international health officials acknowledged significant uncertainty over the scale of the crisis.

Angelini Pharma has agreed to acquire Florida-based Catalyst Pharmaceuticals (CPRX) for $4.1bn, marking the Italian group's debut in the US pharmaceutical market and the second significant American acquisition by an Italian drugmaker in as many weeks.

BridgeBio Pharma has presented late-stage data suggesting its transthyretin amyloidosis drug Attruby could gain an edge over Pfizer's tafamidis franchise in ATTR-CM, a closely watched rare heart-disease market.

Mankind Pharma (MNKI.NS) reported a sharp rise in quarterly profit on Tuesday, buoyed by robust demand for chronic therapies and consumer healthcare products, as the Indian drugmaker outpaced broader market growth at home even as rivals struggled with deteriorating conditions in the United States.

Sanofi [SNY] is stepping up its commitment to rare disease through two distinct partnerships, as the French pharmaceutical group seeks to strengthen its specialty care franchise and improve outcomes for patients with underdiagnosed conditions.

Novo Nordisk [NVO] suffered a setback to its drug pipeline on Tuesday after a treatment at the centre of a major acquisition produced disappointing results in a clinical trial for heart failure patients.

Jazz Pharmaceuticals, the Dublin-headquartered drugmaker, has delivered a markedly stronger first-quarter performance than analysts had anticipated, capping a twelve-month period in which the stock has more than doubled — and prompting a fresh debate over whether the equity now offers meaningful upside or has caught up with the underlying fundamentals.